Search
Close this search box.

Next Gen High Level Design of Facility Layout

Develop a Generation 2 solution in the form of a stand-alone facility layout, equipment list, project delivery methodology, high level cost estimate and implementation schedule.
Categories
Drug substance
Equipment and Supplies
Project status
49% Completed

Industry Need

Clarity on which technology and regulatory projects will deliver the vision for the future.

Solution

Conduct more detailed design and engineering to show value of NIIMBL projects.

Outputs/Deliverables

  • 1st Gen Facility Design (done)
  • Equipment URS – 1Q2024
  • 2nd Gen Facility Design – 2Q2024
  • List of projects that enable 2nd gen design – 3Q2024

Impacts

Detailed business case for integrated continuous bioprocessing (ICB) with capital cost estimates.

Line of sight from corporate manufacturing goals to NIIMBL projects.

Additional Project Information (Members Only)

Login to the NIIMBL member portal to access more, including: 

  • Updates
  • Value Proposition
  • Related Publications
  • Deliverables

Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.

Project Lead

NIIMBL

NIIMBL

Participating Organizations

Amgen Inc.

Amgen Inc.

AstraZeneca

AstraZeneca

Bristol-Myers Squibb

Bristol-Myers Squibb

CSL Behring, LLC

CSL Behring, LLC

Cytiva

Cytiva

Eli Lilly and Company

Eli Lilly and Company

Genentech

Genentech

GlaxoSmithKline, LLC

GlaxoSmithKline, LLC

IPS-Integrated Project Services, LLC

IPS-Integrated Project Services, LLC

Janssen Research & Development, LLC

Janssen Research & Development, LLC

Merck Sharp & Dohme LLC

Merck Sharp & Dohme LLC

MilliporeSigma/EMD Serono

MilliporeSigma/EMD Serono

Pfizer, Inc.

Pfizer, Inc.

Sanofi

Sanofi

Sartorius Stedim

Sartorius Stedim

Takeda Pharmaceuticals

Takeda Pharmaceuticals